Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 3/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 7/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | FDPS | P14324 | 1/20 | 0.34 |
| ▸ | PRKCI | P41743 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10607972 | 0.76 | CES1 (0.48) | ALDH1A1 | |
| SCHEMBL21450873 | 0.74 | ALDH1A1 (0.46) | CYP1A2CYP3A4CYP2C9CYP2C19ALDH1A1 | |
| SCHEMBL2704302 | 0.74 | LOXL2 (0.48) | CYP1A2CYP3A4CYP2C9CYP2C19ALDH1A1 | |
| SCHEMBL6471026 | 0.73 | CYP19A1 (0.47) | CYP1A2CYP3A4CYP2C9CYP2C19ALDH1A1 | |
| SCHEMBL21169845 | 0.73 | CYP3A4 (0.37) | CYP1A2CYP3A4CYP2D6 | |
| Hydrochloric Acid SCHEMBL17984659 | 0.73 | LOXL2 (0.46) | CYP1A2CYP3A4CYP2C9CYP2C19ALDH1A1 | |
| SCHEMBL9182637 | 0.71 | ALDH1A1 (0.48) | CYP1A2CYP3A4CYP2C9CYP2C19ALDH1A1 | |
| SCHEMBL4514923 | 0.71 | ALDH1A1 (0.43) | CYP1A2CYP3A4CYP2C9CYP2C19ALDH1A1 | |
| SCHEMBL5943952 | 0.70 | CYP19A1 (0.48) | CYP1A2CYP3A4CYP2C9CYP2C19ALDH1A1 | |
| Pyridine 4-Methanol SCHEMBL102606 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10654818-B2 | Furane derivatives as inhibitors of ATAD2 | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2020-05-19 | — | — | US | disclosed |
| US-20190218196-A1 | FURANE DERIVATIVES AS INHIBITORS OF ATAD2 | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190218196-A1 | FURANE DERIVATIVES AS INHIBITORS OF ATAD2 | ATAD2, ATAD2B, TAF1L | CYP1A2 1559/4885CYP3A4 2947/4885CYP2C9 3177/4885 |
| US-10654818-B2 | Furane derivatives as inhibitors of ATAD2 | ATAD2, ATAD2B, TAF1L | CYP1A2 1559/4885CYP3A4 2947/4885CYP2C9 3177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.